Top

BMC Cancer

Published in:

Open Access 01-12-2015 | Research article

The preoperative SUVmax for ¹⁸F-FDG uptake predicts survival in patients with colorectal cancer

Authors: Debing Shi, Guoxiang Cai, Junjie Peng, Dawei Li, Xinxiang Li, Ye Xu, Sanjun Cai

Published in: BMC Cancer | Issue 1/2015

Abstract

Background

The study was to investigate whether ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) uptake, analyzed by positron emission tomography (PET), can be used preoperatively to predict survival in Chinese patients with colorectal carcinoma.

Methods

A prospectively maintained colorectal cancer database was retrospectively reviewed between June 2009 and December 2011. All included patients had been newly diagnosed with colorectal cancer (of various stages) and evaluated by ¹⁸F-FDG-PET/computed tomography (CT) within the 2 weeks preceding surgery. Univariate and multivariate analyses were used to determine whether the maximal standardized uptake value (SUVmax) and various clinicopathological and immunohistochemical factors were correlated with survival. Receiver operating characteristics (ROC) curve and Kaplan-Meier survival curve analyses were used to explore whether SUVmax could predict survival in these patients.

Results

A total of 107 patients were enrolled in the study (mean age, 59.26 ± 12.66 years; 66.35 % males), with 77 surviving to the end of follow-up (average 60 months). Univariate analysis indicated that tumor size, TNM stage, nodal metastasis, the ratio of metastasized nodes to retrieved nodes, cyclin D1 immunostaining and SUVmax correlated with survival (P < 0.05). Multivariate analysis showed that only TNM stage and SUVmax were associated with survival (P < 0.05). ROC curve analysis determined the optimal SUVmax cutoff for predicting survival to be 11.85 (sensitivity, 73.3 %; specificity, 75.3 %). Survival was significantly longer in patients with preoperative SUVmax ≤11.85 (P < 0.001, log-rank test).

Conclusions

SUVmax, measured by ¹⁸F-FDG-PET/CT, provides a useful preoperative prognostic factor for patients with colorectal cancer.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRef

Shanghai Municipal Center for Disease Control and Prevention. Shanghai Cancer Report. Shanghai: SCDC; 2007.

Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42:2212–21.PubMedCrossRef

Yoo PS, Lopez-Soler RI, Longo WE, Cha CH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer. 2006;6:202–7.PubMedCrossRef

Pihl E, Hughes ES, McDermott FT, Johnson WR, Katrivessis H. Lung recurrence after curative surgery for colorectal cancer. Dis Colon Rectum. 1987;30:417–9.PubMedCrossRef

Foster JH. Treatment of metastatic disease of the liver: a skeptic's view. Semin Liver Dis. 1984;4:170–9.PubMedCrossRef

O'Connor OJ, McDermott S, Slattery J, Sahani D, Blake MA. The Use of PET-CT in the Assessment of Patients with Colorectal Carcinoma. Int J Surg Oncol. 2011;2011:846512.PubMedPubMedCentral

Farquharson AL, Chopra A, Ford A, Matthews S, Amin SN, De Noronha R. Incidental focal colonic lesions found on (18)Fluorodeoxyglucose positron emission tomography/computed tomography scan: further support for a national guideline on definitive management. Colorectal Dis. 2012;14:e56–63.PubMedCrossRef

Jadvar H, Alavi A, Gambhir SS. 18 F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009;50:1820–7.PubMedPubMedCentralCrossRef

10.

Schneider NI, Langner C. Prognostic stratification of colorectal cancer patients: current perspectives. Cancer Manag Res. 2014;6:291–300.PubMedPubMedCentral

11.

Guzinska-Ustymowicz K, Pryczynicz A, Kemona A, Czyzewska J. Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. Anticancer Res. 2009;29:3049–52.PubMed

12.

Wu HW, Gao LD, Wei GH. hMSH2 and nm23 expression in sporadic colorectal cancer and its clinical significance. Asian Pac J Cancer Prev. 2013;14:1995–8.PubMedCrossRef

13.

Bahnassy AA, Zekri AR, El-Houssini S, El-Shehaby AM, Mahmoud MR, Abdallah S, et al. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol. 2004;4:22.PubMedPubMedCentralCrossRef

14.

Kikuchi M, Mikami T, Sato T, Tokuyama W, Araki K, Watanabe M, et al. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br J Cancer. 2009;101:116–23.PubMedPubMedCentralCrossRef

15.

Tsai HL, Yeh YS, Chang YT, Yang IP, Lin CH, Kuo CH, et al. Co-existence of cyclin D1 and vascular endothelial growth factor protein expression is a poor prognostic factor for UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol. 2013;107:148–54.PubMedCrossRef

16.

Delektorskaya VV, Perevoshchikov AG, Kushlinskii NE. Immunohistological study of NM 23 and C-erbB-2 expression in primary tumor and metastases of colorectal adenocarcinoma. Bull Exp Biol Med. 2003;135:489–94.PubMedCrossRef

17.

Statistical PR. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria; 2009.

18.

Hammer Ø, Harper D, Ryan P. Past: Paleontological Statistics Software Package for education and data analysis. Paleontología Electrónica 4: 1-9. URL: http://palaeo-electronica.org/2001_1/past/issue1_01.htm. 2001.

19.

Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254–61.PubMedCrossRef

20.

Evangelista L, Cervino AR, Michieletto S, Saibene T, Orvieto E, Bozza F et al. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT. Q J Nucl Med Mol Imaging. 2014.

21.

Hsu WH, Hsu PK, Wang SJ, Lin KH, Huang CS, Hsieh CC, et al. Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma. Ann Thorac Surg. 2009;87:1564–8.PubMedCrossRef

22.

Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin Nucl Med. 2003;28:815–20.PubMedCrossRef

23.

Bastiaannet E, Oyen WJ, Meijer S, Hoekstra OS, Wobbes T, Jager PL, et al. Impact of [18 F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg. 2006;93:243–9.PubMedCrossRef

24.

Akhurst T, Larson SM. Positron emission tomography imaging of colorectal cancer. Semin Oncol. 1999;26:577–83.PubMed

25.

Sanli Y, Kuyumcu S, Ozkan ZG, Kilic L, Balik E, Turkmen C, et al. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med. 2012;26:551–8.PubMedCrossRef

26.

Han A, Xue J, Zhu D, Zheng J, Yue J, Yu J. Clinical value of (18)F-FDG PET/CT in postoperative monitoring for patients with colorectal carcinoma. Cancer Epidemiol. 2011;35:497–500.PubMedCrossRef

27.

Chen LB, Tong JL, Song HZ, Zhu H, Wang YC. (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol. 2007;13:5025–9.PubMedPubMedCentralCrossRef

28.

Weston BR, Iyer RB, Qiao W, Lee JH, Bresalier RS, Ross WA. Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center. Cancer. 2010;116:1454–61.PubMedCrossRef

29.

Andersen KF, Skougaard K, Nielsen AL, Hendel HW. Impact of third-line treatment with irinotecan plus cetuximab on non-tumor standardized uptake values in patients with metastatic colorectal cancer. Oncol Lett. 2012;4:131–4.PubMedPubMedCentral

30.

Sarikaya I, Bloomston M, Povoski SP, Zhang J, Hall NC, Knopp MV, et al. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol. 2007;5:64.PubMedPubMedCentralCrossRef

31.

Peng J, He Y, Xu J, Sheng J, Cai S, Zhang Z. Detection of incidental colorectal tumours with 18 F-labelled 2-fluoro-2-deoxyglucose positron emission tomography/computed tomography scans: results of a prospective study. Colorectal Dis. 2011;13:e374–8.PubMedCrossRef

32.

Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology. 1998;206:755–60.PubMedCrossRef

33.

Mukai M, Sadahiro S, Yasuda S, Ishida H, Tokunaga N, Tajima T, et al. Preoperative evaluation by whole-body 18 F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep. 2000;7:85–7.PubMed

34.

Yu L, Tian M, Gao X, Wang D, Qin Y, Geng J. The method and efficacy of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for diagnosing the lymphatic metastasis of colorectal carcinoma. Acad Radiol. 2012;19:427–33.PubMedCrossRef

35.

O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–5.PubMedCrossRef

36.

Kornprat P, Pollheimer MJ, Lindtner RA, Schlemmer A, Rehak P, Langner C. Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal. Am J Clin Oncol. 2011;34:43–9.PubMedCrossRef

37.

Fodor IK, Hutchins GG, Espiritu C, Quirke P, Jubb AM. Prognostic and predictive significance of proliferation in 867 colorectal cancers. J Clin Pathol. 2012;65:989–95.PubMedCrossRef

38.

McKay JA, Douglas JJ, Ross VG, Curran S, Loane JF, Ahmed FY, et al. Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol. 2002;196:386–93.PubMedCrossRef

39.

Crowe PJ, Yang JL, Berney CR, Erskine C, Ham JM, Fisher R, et al. Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. World J Surg. 2001;25:996–1001.PubMedCrossRef

40.

Ioachim E. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features. Int J Clin Pract. 2008;62:1736–43.PubMedCrossRef

Title: The preoperative SUVmax for 18F-FDG uptake predicts survival in patients with colorectal cancer
Authors: Debing Shi
Guoxiang Cai
Junjie Peng
Dawei Li
Xinxiang Li
Ye Xu
Sanjun Cai
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1991-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study

Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer